Immune Exits Oncology and Narrows Its Focus on Two Promising Drugs

NEW YORK, NY / ACCESSWIRE / October 6, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. The company is conducting two Phase II clinical trials to test its lead drug candidate, bertilimumab, in patients suffering from bullous pemphigoid and ulcerative colitis, respectively.

On September 27th, 2017, IMNP announced positive results from its ongoing Phase II Trial of Bertilimumab in bullous pemphigoid.

These promising preliminary results support the company’s strategy of focusing its human capital and financial resources on its bertilimumab and NanoCyclo product candidates while streamlining operations by divesting its unrelated oncology business.

A full analysis of bertilimumab and NanoCyclo, including potential applications here: READ MORE.

Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/immune/.

Bullous pemphigoid is an autoimmune condition that is imbibed in the immune system creating and adversely affecting the entire antibodies that break down the bonds between skin cells in humans. This breaking down of the bonds translates to open sores and severe blisters.

Moderate-to-severe bullous pemphigoid is typically managed with 60 mg of prednisone. The improvement seen in these subjects despite such a low prednisone dose suggests bertilimumab may provide a clinically meaningful benefit. Bertilimumab could significantly reduce or maybe even eliminate the need for systemic corticosteroids, and their significant toxicity, in the treatment of bullous pemphigoid.

Our report details IMNP corporate events, finances, and the oncology assets divestiture: READ MORE.

Copy and paste to your browser may be required to view the report – http://tradersnewssource.com/immune/.

Disclosure

Traders News Source LLC (“TNS”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, article, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 477181